Beckman Access versus the Bayer ACS:180 and the Abbott AxSYM cardiac Troponin-I real-time immunoassays: an observational prospective study

BMC Emergency Medicine
Robert H BaevskyHoward A Smithline

Abstract

BACKGROUND: Reliability of cardiac troponin-I assays under real-time conditions has not been previously well studied. Most large published cTnI trials have utilized protocols which required the freezing of serum (or plasma) for delayed batch cTnI analysis. We sought to correlate the presence of the acute ischemic coronary syndrome (AICS) to troponin-I values obtained in real-time by three random-mode analyzer immunoassay systems: the Beckman ACCESS (BA), the Bayer ACS:180 (CC) and the Abbott AxSYM (AX). METHODS: This was an observational prospective study at a university tertiary referral center. Serum from a convenience sampling of telemetry patients was analyzed in real-time for troponin-I by either the BA-CC (Arm-1) or BA-AX (Arm-2) assay pairs. Presence of the AICS was determined retrospectively and then correlated with troponin-I results. RESULTS: 100 patients were enrolled in Arm-1 (38 with AICS) and 94 in Arm-2 (48 with AICS). The BA system produced 51% false positives in Arm-1, 44% in Arm-2, with negative predictive values of 92% and 100% respectively. In Arm-1, the BA and the CC assays had sensitivities of 97% and 63% and specificities of 18% and 87%. In Arm-2, the BA and the AX assays had sensitivities of 100% and 83%...Continue Reading

References

Aug 1, 1989·Circulation·E Braunwald
Dec 1, 1996·Clinical Biochemistry·J P BertinchantB Pau
Jul 1, 1997·Human Heredity·I GolovlevaL Beckman
Mar 3, 1999·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·D PateronD Lebrec
May 25, 1999·The American Journal of Emergency Medicine·I A KhanT J Sacchi
Jul 2, 1999·Scandinavian Journal of Clinical and Laboratory Investigation. Supplementum·A KatrukhaK Pettersson
Jul 23, 1999·Intensive Care Medicine·F LagneauJ Marty
Aug 18, 1999·Clinica Chimica Acta; International Journal of Clinical Chemistry·F S Apple
Aug 18, 1999·Clinica Chimica Acta; International Journal of Clinical Chemistry·A H Wu, L Ford
Dec 3, 1999·QJM : Monthly Journal of the Association of Physicians·A ChiuC H Choi
Dec 22, 1999·Clinical Chemistry and Laboratory Medicine : CCLM·Z ZamanN Blanckaert
Dec 22, 1999·The American Journal of Cardiology·W F FearonV F Froelicher
Dec 29, 1999·Vascular Medicine·D B Sacks
Feb 25, 2000·Clinica Chimica Acta; International Journal of Clinical Chemistry·K T YeoT F Fitzmaurice
Mar 22, 2000·Clinical Chemistry and Laboratory Medicine : CCLM·A KatrukhaT Esakova
Apr 20, 2000·The New England Journal of Medicine·J H PopeH P Selker
Sep 20, 2000·Mayo Clinic Proceedings·G S Reeder
Oct 5, 2001·Journal of the American College of Cardiology·A S Jaffe
Dec 26, 2002·American Journal of Obstetrics and Gynecology·George H ShadeJulius M Gardin
Dec 6, 2003·Clinical Chemistry·Mauro PanteghiniUNKNOWN Committee on Standardization of Markers of Cardiac Damage of the IFCC
May 13, 2004·The American Journal of Emergency Medicine·Reena Duseja, James A Feldman
Jan 12, 2011·Clinica Chimica Acta; International Journal of Clinical Chemistry·A K SaengerA S Jaffe

❮ Previous
Next ❯

Methods Mentioned

BETA
serum collection
blood draws

Software Mentioned

ACCESS
Stata
Excel

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.